we have not received any of the amounts indicated by the district court in its final judgment . the injunctive relief included : ( 1 ) enjoining bd 's use of world 's sharpest needle or any similar assertion of superior sharpness ; ( 2 ) requiring notification to all customers who purchased bd syringe products from july 2 , 2004 to date that bd wrongfully claimed that its syringe needles were sharper and that its statement that it had data on file was false and misleading ; ( 3 ) requiring notification to employees , customers , distributors , gpos , and government agencies that the deadspace of the vanishpoint ® has been within iso standards since 2004 and that bd overstated the deadspace of the vanishpoint ® to represent that it was higher than some of bd 's syringes when it was actually less , and that bd 's statement that it had data on file was false and misleading , and , in addition , posting this notice on its website for a period of three years ; ( 4 ) enjoining bd from advertising that its syringe products save medication as compared to vanishpoint ® products for a period of three years ; ( 5 ) requiring notification to all employees , customers , distributors , gpos , and government agencies that bd 's website , cost calculator , printed materials , and oral representations alleging bd 's syringes save medication as compared to the vanishpoint ® were based on false and inaccurate measurement of the vanishpoint ® , and , in addition , posting this notice on its website for a period of three years ; and ( 6 ) requiring the implementation of a comprehensive training program for bd employees and distributors that specifically instructs them not to use old marketing materials and not to make false representations regarding vanishpoint ® syringes . bd has appealed to the united states court of appeals for the fifth circuit . oral argument was heard on february 29 , 2016 and no order has issued . on september 30 , 2013 , we received payment of $ 7,724,826 ( the judgment amount ) from bd pursuant to a stipulation in the patent infringement case retractable technologies , inc. and thomas shaw v. becton dickinson and company , civil action no . 2:07-cv-250 , in the u.s. district court for the eastern district of texas , 16 marshall division . the judgment amount was included as income in the second quarter of 2015 due to the conclusion of the case and related appeals . prior to the second quarter of 2015 , the judgment amount had been shown as a liability on the balance sheet since we were paid the judgment amount and the litigation did not come to a final conclusion until the second quarter of 2015. in 2014 , we took steps to decrease our non-litigation legal costs by approximately $ 1.1 million . additionally , effective may 9 , 2014 , we reduced our workforce by 13.7 % in an effort to cut costs . in 2015 , we further reduced our workforce , including our acceptance of the resignation of steven r. wisner , a former executive officer , on may 29 , 2015. mr. wisner was granted a one-time payment in connection with his resignation . the net effect of the lower non-litigation costs and the reduced workforce , offset by the payment to mr. wisner , was approximately $ 450,000 in 2015. in the future , if such cost cutting measures prove insufficient , we may reduce the number of units being produced , further reduce the workforce , further reduce the salaries of officers as well as other employees , and or defer royalty payments . section 4191 of the internal revenue code , enacted by the health care and education reconciliation act of 2010 in conjunction with the patient protection and affordable care act provides for an excise tax of 2.3 % on medical devices . the excise tax was applicable to domestic sales of our products , except those which are sold to exempt organizations . the majority of our sales are domestic and not in the retail market . the tax was imposed on sales , not profits . we have not passed this tax along to our customers . the impact of this tax was $ 360,000 in 2015 , $ 856,000 in 2014 , and $ 758,000 in 2013 , and is net of expected refunds attributable to rebate credits . the consolidated appropriations act , 2016 ( pub . l. 114-113 ) , signed into law on december 18 , 2015 , includes a two year moratorium on the medical device excise tax imposed by internal revenue code section 4191. thus , the medical device excise tax does not apply to the sale of a taxable medical device by the manufacturer , producer , or importer of the device during the period beginning on january 1 , 2016 and ending on december 31 , 2017. we exchanged 728,000 shares of common stock for 200,000 shares of our series iv class b convertible preferred stock as of november 30 , 2015 pursuant to an agreement with a shareholder . such shareholder agreed to waive all unpaid dividends in arrears associated with the tendered preferred stock , equaling $ 3,094,795. future dividend requirements of $ 200,000 per year are avoided as a result of this transaction . product purchases from our primary chinese manufacturer have enabled us to increase manufacturing capacity with little capital outlay and have provided a competitive manufacturing cost . in 2015 , our chinese manufacturer produced approximately 77.7 % of our vanishpoint ® finished products . story_separator_special_tag in the event that we become unable to purchase products from our primary chinese manufacturer , we would need to find an alternate manufacturer for the 0.5ml insulin syringe , the 0.5ml autodisable syringe , and the 2ml , 5ml , and 10ml syringes and we would increase domestic production for the 1ml and 3ml syringes . in 1995 , we entered into a license agreement with thomas j. shaw for the exclusive right to manufacture , market , and distribute products utilizing automated retraction technology . this technology is the subject of various patents and patent applications owned by mr. shaw . the license agreement generally provides for quarterly payments of a 5 % royalty fee on gross sales . with increased volumes , our manufacturing unit costs have generally tended to decline . factors that could affect our unit costs include increases in costs by third party manufacturers , changing production volumes , costs of petroleum products , and transportation costs . increases in such costs may not be recoverable through price increases of our products . results of operations the following discussion contains trend information and other forward-looking statements that involve a number of risks and uncertainties . our actual future results could differ materially from our historical results of operations and those discussed in the forward-looking statements . all period references are to our fiscal years ended december 2015 , 2014 , or 2013. dollar amounts have been rounded for ease of reading . 17 comparison of year ended december 31 , 2015 and year ended december 31 , 2014 domestic sales accounted for 77.9 % and 80.1 % of the revenues in 2015 and 2014 , respectively . domestic revenues decreased 16.7 % principally due to reduced flu demand . domestic unit sales decreased 17.6 % . domestic unit sales were 67.0 % of total unit sales for 2015. international revenues decreased from $ 6.9 million in 2014 to $ 6.5 million in 2015 , primarily due to more restrictive qualification requirements by the company . overall unit sales decreased 11.9 % . our international orders may be subject to significant fluctuation over time . such orders may fluctuate due to health initiatives at various times as well as economic conditions . cost of sales decreased $ 3.3 million principally due to lower volumes . royalty expense decreased $ 251 thousand due to decreased gross sales . gross profit margins increased from 34.8 % in 2014 to 35.8 % in 2015. operating expenses decreased 2.9 % from the prior year due to decreased medical device excise taxes attributable to refunds , lower compensation costs , and lower travel and entertainment costs . a non-recurring recognition of $ 7,724,826 received from bd in the second quarter of 2015 pursuant to a patent infringement case had a significant impact on 2015 income . recognizing this payment also significantly decreased 2015 current liabilities on the balance sheets . the loss from operations was $ 3.2 million in 2015 compared to an operating loss of $ 2.2 million in 2014. earnings per share were positively affected by our acquisition of 200,000 shares of series iv class b convertible preferred stock . under the guidelines of asc 260-10-s99-2 , effect on the calculation of earnings per share for the redemption or induced conversion of preferred stock , we reflected the gain on extinguishment of this preferred stock in net income per common stockholder used to calculate earnings per share . cash flow from operations was a negative $ 3.3 million for 2015 due primarily to the loss from operations and changes in working capital , namely increased inventories and other current assets , mitigated by a decrease in accounts receivable and an increase in accounts payable . comparison of year ended december 31 , 2014 and year ended december 31 , 2013 domestic sales accounted for 80.1 % and 80.7 % of the revenues in 2014 and 2013 , respectively . domestic revenues increased 11.3 % principally due to increased unit sales . domestic unit sales increased 11.8 % . domestic unit sales were 71.6 % of total unit sales for 2014. international revenues increased from $ 5.9 million in 2013 to $ 6.9 million in 2014 , primarily due to increased unit sales and an increase in average price . overall unit sales increased 12.0 % . our international orders may be subject to significant fluctuation over time . such orders may fluctuate due to health initiatives at various times as well as economic conditions . cost of sales increased $ 2.0 million due to an increase in units sold mitigated by a slightly lower unit cost of manufacture . royalty expense increased $ 254 thousand due to increased gross sales . gross profit margins increased from 33.5 % in 2013 to 34.8 % in 2014. operating expenses decreased 12.7 % from the prior year due to decreased cost of non-litigation legal expense , lower compensation cost , and decreased office expenses which is the result of cost-cutting measures implemented in 2014. the loss from operations was $ 2.2 million in 2014 compared to an operating loss of $ 5.9 million in 2013 , a 63.6 % decrease . cash flow from operations was a negative $ 3.9 million for 2014 due primarily to our increase in accounts receivable , decrease in current liabilities , and our loss from operations , mitigated by a decrease in inventory and depreciation . liquidity and capital resources at the present time , management does not intend to raise equity capital . due to the funds received from prior litigation , we have sufficient cash reserves and intend to rely on operations , cash reserves , and debt financing , when available , as the primary ongoing sources of cash . our ability to obtain additional funds through loans is 18 uncertain . our financial statements do not reflect a 2015 judgment in our favor for $ 352 million plus post-judgment interest .

cash requirements due to funds received from prior litigation , we have sufficient cash reserves and intend to rely on operations , cash reserves , and debt financing , when available , as the primary ongoing sources of cash . we have taken steps to decrease our non-litigation legal costs and we continue to evaluate these costs . additionally , since the beginning of 2014 , we have reduced our workforce . in the future , if such cost cutting measures prove insufficient , we may reduce the number of units being produced , further reduce the workforce , further reduce the salaries of officers and other employees , and or defer royalty payments . external sources of liquidity we have obtained several loans from our inception , which have , together with the proceeds from the sales of equities and litigation efforts , enabled us to pursue development and production of our products . our ability to obtain additional funds through loans is uncertain . due to the current market price of our common stock , it is unlikely we would choose to raise funds by the sale of equity . 19 on september 30 , 2013 , we received payment of $ 7,724,826 ( the judgment amount ) from bd pursuant to a stipulation in the patent infringement case retractable technologies , inc. and thomas shaw v. becton dickinson and company , civil action no .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash requirements due to funds received from prior litigation , we have sufficient cash reserves and intend to rely on operations , cash reserves , and debt financing , when available , as the primary ongoing sources of cash . we have taken steps to decrease our non-litigation legal costs and we continue to evaluate these costs . additionally , since the beginning of 2014 , we have reduced our workforce . in the future , if such cost cutting measures prove insufficient , we may reduce the number of units being produced , further reduce the workforce , further reduce the salaries of officers and other employees , and or defer royalty payments . external sources of liquidity we have obtained several loans from our inception , which have , together with the proceeds from the sales of equities and litigation efforts , enabled us to pursue development and production of our products . our ability to obtain additional funds through loans is uncertain . due to the current market price of our common stock , it is unlikely we would choose to raise funds by the sale of equity . 19 on september 30 , 2013 , we received payment of $ 7,724,826 ( the judgment amount ) from bd pursuant to a stipulation in the patent infringement case retractable technologies , inc. and thomas shaw v. becton dickinson and company , civil action no .
```    
 Suspicious Activity Report : we have not received any of the amounts indicated by the district court in its final judgment . the injunctive relief included : ( 1 ) enjoining bd 's use of world 's sharpest needle or any similar assertion of superior sharpness ; ( 2 ) requiring notification to all customers who purchased bd syringe products from july 2 , 2004 to date that bd wrongfully claimed that its syringe needles were sharper and that its statement that it had data on file was false and misleading ; ( 3 ) requiring notification to employees , customers , distributors , gpos , and government agencies that the deadspace of the vanishpoint ® has been within iso standards since 2004 and that bd overstated the deadspace of the vanishpoint ® to represent that it was higher than some of bd 's syringes when it was actually less , and that bd 's statement that it had data on file was false and misleading , and , in addition , posting this notice on its website for a period of three years ; ( 4 ) enjoining bd from advertising that its syringe products save medication as compared to vanishpoint ® products for a period of three years ; ( 5 ) requiring notification to all employees , customers , distributors , gpos , and government agencies that bd 's website , cost calculator , printed materials , and oral representations alleging bd 's syringes save medication as compared to the vanishpoint ® were based on false and inaccurate measurement of the vanishpoint ® , and , in addition , posting this notice on its website for a period of three years ; and ( 6 ) requiring the implementation of a comprehensive training program for bd employees and distributors that specifically instructs them not to use old marketing materials and not to make false representations regarding vanishpoint ® syringes . bd has appealed to the united states court of appeals for the fifth circuit . oral argument was heard on february 29 , 2016 and no order has issued . on september 30 , 2013 , we received payment of $ 7,724,826 ( the judgment amount ) from bd pursuant to a stipulation in the patent infringement case retractable technologies , inc. and thomas shaw v. becton dickinson and company , civil action no . 2:07-cv-250 , in the u.s. district court for the eastern district of texas , 16 marshall division . the judgment amount was included as income in the second quarter of 2015 due to the conclusion of the case and related appeals . prior to the second quarter of 2015 , the judgment amount had been shown as a liability on the balance sheet since we were paid the judgment amount and the litigation did not come to a final conclusion until the second quarter of 2015. in 2014 , we took steps to decrease our non-litigation legal costs by approximately $ 1.1 million . additionally , effective may 9 , 2014 , we reduced our workforce by 13.7 % in an effort to cut costs . in 2015 , we further reduced our workforce , including our acceptance of the resignation of steven r. wisner , a former executive officer , on may 29 , 2015. mr. wisner was granted a one-time payment in connection with his resignation . the net effect of the lower non-litigation costs and the reduced workforce , offset by the payment to mr. wisner , was approximately $ 450,000 in 2015. in the future , if such cost cutting measures prove insufficient , we may reduce the number of units being produced , further reduce the workforce , further reduce the salaries of officers as well as other employees , and or defer royalty payments . section 4191 of the internal revenue code , enacted by the health care and education reconciliation act of 2010 in conjunction with the patient protection and affordable care act provides for an excise tax of 2.3 % on medical devices . the excise tax was applicable to domestic sales of our products , except those which are sold to exempt organizations . the majority of our sales are domestic and not in the retail market . the tax was imposed on sales , not profits . we have not passed this tax along to our customers . the impact of this tax was $ 360,000 in 2015 , $ 856,000 in 2014 , and $ 758,000 in 2013 , and is net of expected refunds attributable to rebate credits . the consolidated appropriations act , 2016 ( pub . l. 114-113 ) , signed into law on december 18 , 2015 , includes a two year moratorium on the medical device excise tax imposed by internal revenue code section 4191. thus , the medical device excise tax does not apply to the sale of a taxable medical device by the manufacturer , producer , or importer of the device during the period beginning on january 1 , 2016 and ending on december 31 , 2017. we exchanged 728,000 shares of common stock for 200,000 shares of our series iv class b convertible preferred stock as of november 30 , 2015 pursuant to an agreement with a shareholder . such shareholder agreed to waive all unpaid dividends in arrears associated with the tendered preferred stock , equaling $ 3,094,795. future dividend requirements of $ 200,000 per year are avoided as a result of this transaction . product purchases from our primary chinese manufacturer have enabled us to increase manufacturing capacity with little capital outlay and have provided a competitive manufacturing cost . in 2015 , our chinese manufacturer produced approximately 77.7 % of our vanishpoint ® finished products . story_separator_special_tag in the event that we become unable to purchase products from our primary chinese manufacturer , we would need to find an alternate manufacturer for the 0.5ml insulin syringe , the 0.5ml autodisable syringe , and the 2ml , 5ml , and 10ml syringes and we would increase domestic production for the 1ml and 3ml syringes . in 1995 , we entered into a license agreement with thomas j. shaw for the exclusive right to manufacture , market , and distribute products utilizing automated retraction technology . this technology is the subject of various patents and patent applications owned by mr. shaw . the license agreement generally provides for quarterly payments of a 5 % royalty fee on gross sales . with increased volumes , our manufacturing unit costs have generally tended to decline . factors that could affect our unit costs include increases in costs by third party manufacturers , changing production volumes , costs of petroleum products , and transportation costs . increases in such costs may not be recoverable through price increases of our products . results of operations the following discussion contains trend information and other forward-looking statements that involve a number of risks and uncertainties . our actual future results could differ materially from our historical results of operations and those discussed in the forward-looking statements . all period references are to our fiscal years ended december 2015 , 2014 , or 2013. dollar amounts have been rounded for ease of reading . 17 comparison of year ended december 31 , 2015 and year ended december 31 , 2014 domestic sales accounted for 77.9 % and 80.1 % of the revenues in 2015 and 2014 , respectively . domestic revenues decreased 16.7 % principally due to reduced flu demand . domestic unit sales decreased 17.6 % . domestic unit sales were 67.0 % of total unit sales for 2015. international revenues decreased from $ 6.9 million in 2014 to $ 6.5 million in 2015 , primarily due to more restrictive qualification requirements by the company . overall unit sales decreased 11.9 % . our international orders may be subject to significant fluctuation over time . such orders may fluctuate due to health initiatives at various times as well as economic conditions . cost of sales decreased $ 3.3 million principally due to lower volumes . royalty expense decreased $ 251 thousand due to decreased gross sales . gross profit margins increased from 34.8 % in 2014 to 35.8 % in 2015. operating expenses decreased 2.9 % from the prior year due to decreased medical device excise taxes attributable to refunds , lower compensation costs , and lower travel and entertainment costs . a non-recurring recognition of $ 7,724,826 received from bd in the second quarter of 2015 pursuant to a patent infringement case had a significant impact on 2015 income . recognizing this payment also significantly decreased 2015 current liabilities on the balance sheets . the loss from operations was $ 3.2 million in 2015 compared to an operating loss of $ 2.2 million in 2014. earnings per share were positively affected by our acquisition of 200,000 shares of series iv class b convertible preferred stock . under the guidelines of asc 260-10-s99-2 , effect on the calculation of earnings per share for the redemption or induced conversion of preferred stock , we reflected the gain on extinguishment of this preferred stock in net income per common stockholder used to calculate earnings per share . cash flow from operations was a negative $ 3.3 million for 2015 due primarily to the loss from operations and changes in working capital , namely increased inventories and other current assets , mitigated by a decrease in accounts receivable and an increase in accounts payable . comparison of year ended december 31 , 2014 and year ended december 31 , 2013 domestic sales accounted for 80.1 % and 80.7 % of the revenues in 2014 and 2013 , respectively . domestic revenues increased 11.3 % principally due to increased unit sales . domestic unit sales increased 11.8 % . domestic unit sales were 71.6 % of total unit sales for 2014. international revenues increased from $ 5.9 million in 2013 to $ 6.9 million in 2014 , primarily due to increased unit sales and an increase in average price . overall unit sales increased 12.0 % . our international orders may be subject to significant fluctuation over time . such orders may fluctuate due to health initiatives at various times as well as economic conditions . cost of sales increased $ 2.0 million due to an increase in units sold mitigated by a slightly lower unit cost of manufacture . royalty expense increased $ 254 thousand due to increased gross sales . gross profit margins increased from 33.5 % in 2013 to 34.8 % in 2014. operating expenses decreased 12.7 % from the prior year due to decreased cost of non-litigation legal expense , lower compensation cost , and decreased office expenses which is the result of cost-cutting measures implemented in 2014. the loss from operations was $ 2.2 million in 2014 compared to an operating loss of $ 5.9 million in 2013 , a 63.6 % decrease . cash flow from operations was a negative $ 3.9 million for 2014 due primarily to our increase in accounts receivable , decrease in current liabilities , and our loss from operations , mitigated by a decrease in inventory and depreciation . liquidity and capital resources at the present time , management does not intend to raise equity capital . due to the funds received from prior litigation , we have sufficient cash reserves and intend to rely on operations , cash reserves , and debt financing , when available , as the primary ongoing sources of cash . our ability to obtain additional funds through loans is 18 uncertain . our financial statements do not reflect a 2015 judgment in our favor for $ 352 million plus post-judgment interest .

